Cantargia AB (publ) (FRA:7V3)

Market Cap	94.58M
Revenue (ttm)	27.92M
Net Income (ttm)	12.66M
Shares Out	n/a
EPS (ttm)	0.05
PE Ratio	7.47
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,974
Average Volume	549
Open	0.3515
Previous Close	0.3445
Day's Range	0.3515 - 0.3965
52-Week Range	0.0635 - 0.3965
Beta	n/a
RSI	62.05
Earnings Date	Feb 20, 2026

About Cantargia AB

Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in phase 1 clinical trial for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It also develops...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2009
• Employees: 22
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 7V3

Financial Performance

Financial numbers in SEK